Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02709512 · ClinicalTrials.gov registry record · Phase 2
Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
A Phase 2 study, sponsored by Polaris Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 249
- Enrollment target
NCT02709512 is a Phase 2 study that has completed, run by Polaris Group. The registered enrollment target is 249 participants.
The verdict
NCT02709512, a Phase 2 study, has completed, sponsored by Polaris Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 249 participants
- Enrollment target
Study Summary
This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die.
Interventions
- DRUG ADI-PEG 20 plus Pem Platinum
- OTHER Placebo plus Pem Platinum
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2022-08-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02709512
The ClinicalTrials.gov registry entry for NCT02709512 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 249 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Polaris Group, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ADI-PEG 20 plus Pem Platinum is the first listed.
NCT02709512 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02709512 about?
NCT02709512 is a clinical study titled "Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin". This is a study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-P...
What is the current status of trial NCT02709512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 249 participants. The study started on 2017-08-01. Estimated completion is 2022-08-15.
What interventions are being tested in trial NCT02709512?
The interventions under investigation include: ADI-PEG 20 plus Pem Platinum (DRUG), Placebo plus Pem Platinum (OTHER).
Who is sponsoring clinical trial NCT02709512?
This trial is sponsored by Polaris Group, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.